Kemper Corporation (KMPR): what the price assumes

In the published model solve dated 2026-Q2, anchored at $27.93, Kemper Corporation (KMPR) is priced for 8.0% return on equity. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-06-27.

Generated: 2026-08-30 · Source: https://boothcheck.com/report/KMPR

Headline

FieldValue
TickerKMPR
CompanyKemper Corporation
Current price$27.93/sh
CompositionSpecialty Property & Casualty Insurance 88% / Life Insurance 12%

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basisfinancials
Return on equity needed8.0%
Return on equity now5.3%
ROE gap+2.7pp
Price-to-book0.75x

Solve inputs: computed at a 9.3% cost of equity with 4% terminal growth over a 10-year stage, on common book equity (FY2026).

How unusual the bet is: within-range

ReferenceValue
vs own history+0.55σ
cohort percentile (of 78 peers)8
sustained it ~10 years at this level82%
implied end-window share0%

Valuation X-Ray

The price is supported by asset-based value, while growth-DCF lands below the price. A value/asset-supported name, not a pure growth bet.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset0.79x2justifies
Earnings—0—
Relative—0—
Growth8.70x1expensive

Families that justify the price: Asset Families that call it expensive: Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 7.3%); the inversion above states its own rate.

Per-Model Detail (n=3)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth——no—
Bank Fair Value (P/TBV)———no—
Relative ValuationRelative——noP/S fallback (negative EPS): Sector P/S 1.2x × TTM revenue — excluded from consensus
Simple DDMGrowth$3.218.70xyesDPS $1.31, g=-22.4% (sustainable: ROE (TTM) × retention; not the terminal-growth assumption), ke=9.3%
Two-Stage DDMGrowth$-16.18—noStage 1: -200% for 5yr, Stage 2: 3.5% perpetual
Simple Excess ReturnAsset$37.480.75xyesReference only (book value floor): BV/sh $37.48, ROE negative
Two-Stage Excess ReturnAsset$33.730.83xyesReference only (book value with convergence): BV/sh $37.48, ROE converges to ke
Discounted Future Market CapGrowth——noRev $4.6B, growth -4% (input: historical growth; tapered), Terminal P/S: 0.3x / 0.4x / 0.4x (bear / base = today's held flat / bull, cap 8x)
Peter Lynch Fair ValueRelative——noNegative/zero EPS — earnings-based value floored at $0
Margin TrajectoryGrowth——no—
Earnings Power ValueEarnings——no—
Residual IncomeAsset——no—
Graham NumberAsset——no—
EV/EBITDA RelativeRelative——no—
FCF YieldEarnings——no—
SBC-Adj FCF YieldEarnings——no—
Ben Graham FormulaEarnings——no—
ROIC-Justified P/BAsset——no—
P/Sales SectorRelative——no—
PEG Fair ValueRelative——no—
Earnings YieldEarnings——no—
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Economic-Unit Decomposition (Sum Of The Parts)

The issuer is a funded financial business. Debt, interest, and cash flows are operating inputs, so industrial EV, net-debt, WACC, and free-cash-flow lenses do not apply; value the common-equity claim with book, earnings, capital, and payout economics.

UnitRoleValuation basisRevenueReported profitValue evidenceStatus
Specialty Property & Casualty Insurancefinancialequity$4.1b—withheldunresolved standalone equity facts required
Life Insurancefinancialequity$583.2m—withheldunresolved standalone equity facts required

No unit-level total common-equity value is stated. Each financial unit requires supported standalone common equity, normalized earnings, capital adequacy, and payout capacity. Consolidated debt, interest, and cash are operating balances, not an enterprise-to-equity bridge; company-level book, earnings, capital, and payout lenses remain the coherent cross-checks.

Solvency

FieldValue
Share count CAGR (buyback)-2.0%

Deposit/float-funded balance sheet: debt is funding, not corporate leverage, and GAAP operating cash flow follows loan flows. Net-debt, interest-coverage, and cash-burn lenses do not apply. The solvency frame for a financial is regulatory capital and payout capacity (CET1, stress buffer, dividends plus buybacks against earnings).

Bullet Takeaways

Kemper is a mature specialty insurer valued on price-to-book, and at $25.08 the price assumes the company sustains a return on equity of about 7.1% at roughly 0.6x book, above the 5.3% it has been earning recently.

Q1 2026 was a loss: a net loss of $1.7 million, or $0.03 per share, versus a $99.7 million profit a year earlier, as the specialty personal-auto combined ratio blew out to 110.9% on California auto losses.

Book value per share is $45.05 and adjusted book value per share is $27.79, so the stock trades below even the adjusted book figure. The investment case rests entirely on whether rate increases, especially in California, restore underwriting profit.

Bull Case

Kemper has to be read as what it is: a mature specialty insurer, not a growth story, and that framing changes how the numbers should be weighed. A mature insurer is valued on the return it earns on its capital, so the right lens is price-to-book and return on equity, not an earnings multiple or a cash-flow projection, which is why the standard DCF and FCF methods are correctly skipped for a financial. On that lens the picture is straightforward. Book value per share is $45.05, and the stock trades at $25.08 (June 27, 2026), roughly 0.55x book. The reverse-DCF reads the price as assuming a sustained return on equity of only about 7.1%, just above the cost of capital, paying about 0.6x book, in the lower half of the peer group's price-to-book. For a company with a real franchise, that is a low bar.

The franchise is in specialty auto, the nonstandard and underserved drivers that the standard carriers avoid, where Kemper has built distribution and underwriting expertise that is hard to replicate. The economics are normal for the niche: the combined ratio, the sum of the loss ratio and the expense ratio that determines whether underwriting makes money (RLI FY2025 10-K, accession 0001104659-26-018013), runs profitable in the segments not impaired by a single state's problem. Specialty commercial auto posted an underlying combined ratio of 92.4% in Q1 2026, and the Florida and Texas growth markets ran at 93.7% with policies in force up 4.9% sequentially. Those are profitable books growing at attractive returns.

The bull case is mean reversion in the impaired book plus self-help. Initial benefits from California rate increases are expected in Q2 2026, with more meaningful impact in the second half, and management is targeting a medium-term expense ratio below 20% through restructuring. If specialty personal auto returns toward a profitable combined ratio, the consolidated return on equity moves back toward the 7%-plus the price already assumes, and a sub-book-value stock with a $1.25 dividend and a shrinking share count, down about 2% a year, re-rates. Against insurance peers like Old Republic, RLI, and CNA, Kemper offers a focused specialty franchise at a discount to book, with the catalyst being rate adequacy the regulators are now granting.

Bear Case

The variable with the most leverage on Kemper is rate regulation, and the price does not adequately reflect how exposed the company is to it. Kemper writes specialty auto in states where it cannot simply reprice at will; it must file for and win rate increases from insurance regulators, and California, its problem child, has one of the slowest and most adversarial rate-approval regimes in the country. Q1 2026 was the proof: a net loss of $1.7 million driven by California auto losses, with the specialty personal-auto underlying loss-and-LAE ratio jumping to 87.7% from 70.1% and the combined ratio reaching 110.9%. A combined ratio above 100% means the company paid out more in claims and expenses than it collected in premium. When loss costs run ahead of approved rates, the insurer simply loses money until the regulator catches up, and that catch-up is on the regulator's timeline, not Kemper's.

Loss-cost inflation is the macro force behind the rate problem. Kemper's own filing lists the drivers that govern its results, the frequency and severity of insurance claims, catastrophes, and the interest-rate environment (FY2025 10-K, accession 0000860748-26-000014). Auto claim severity, the cost to repair vehicles and settle injury claims, has run hot, and in a regulated, lagged-pricing book that is exactly the squeeze that produced the 110.9% combined ratio. Rate increases help, but they arrive after the damage, and there is no guarantee the approved rates fully cover the next leg of inflation.

The valuation tension is the rest of the bear case. Despite the discount to book, the engine flags that no valuation family reaches the price: it is rich on assets, earnings power, peers, and even forward growth. That is because the asset and earnings methods key off the depressed trailing return on equity near 1.6%, and at that level of profitability the company is barely earning its cost of capital. The price assuming a 7.1% return on equity is a bet that profitability normalizes; if California rate relief disappoints or loss costs reaccelerate, the realized return stays near today's depressed level and the stock is not cheap at all relative to what it actually earns. The dividend at $1.25 is well covered on a normalized basis but strained on the trailing one. A specialty insurer dependent on a hostile rate regulator to restore profitability is the kind of name where the cheap-to-book screen can be a trap.

Valuation

Kemper must be valued on price-to-book and return on equity, the way any insurer is, which is why the cash-flow and operating-multiple methods are correctly gated off for a financial. The reverse-DCF frames it cleanly: at today's price the market assumes Kemper sustains a return on equity of about 7.1%, paying roughly 0.6x book, in the lower half of the peer group's price-to-book. For reference, it has recently been earning about 5.3%, and on a trailing basis far less. So the price embeds a recovery in profitability, not the current run-rate.

The method spread reflects how depressed trailing earnings are. The asset and earnings methods that key off the current return on equity near 1.6% land far below the price, simple excess return near $8, earnings yield near $8, because at that profitability the company barely clears its cost of capital. The dividend and relative methods land in the mid-teens. The Graham Number near $27 is the only conservative method close to the price, on a book value of $45.35.

The honest synthesis is that Kemper is cheap to book but only fairly valued to its current depressed earnings. The investment case is entirely a profitability-recovery case: pay 0.55x book today, and if return on equity normalizes toward 7% or better as California rate increases flow through, the stock re-rates toward book; if profitability stays near the trough, the discount to book is deserved. The balance sheet for an insurer is regulatory capital and payout capacity, not corporate leverage, and on that frame Kemper is adequately capitalized. The variable to underwrite is the combined ratio, not the multiple.

Catalysts

Q1 2026 (reported May 2026) was a clear setback: a net loss of $1.7 million, or $0.03 per share, versus net income of $99.7 million, or $1.54 per diluted share, a year earlier. The driver was the specialty personal-auto book, where the underlying loss-and-LAE ratio rose to 87.7% from 70.1% and the combined ratio hit 110.9%, weighed down by California auto losses. Book value per share was $45.05 and adjusted book value per share $27.79. The next quarterly prints are the entire thesis test.

The defining catalyst is California rate relief. Management expects initial benefits from California rate increases in Q2 2026, with more meaningful impact in the second half of 2026. Watch the specialty personal-auto combined ratio quarter by quarter: a move back below 100% would confirm the recovery, while continued elevation would signal that rate adequacy is still lagging loss costs. Restructuring aimed at a medium-term expense ratio below 20% is the parallel self-help lever.

The other segments and capital return are the secondary signals. Specialty commercial auto, running near a 92.4% combined ratio, and the Florida and Texas growth markets near 93.7% with policies in force up 4.9% sequentially, show the franchise works where pricing is adequate. The $1.25 dividend and continued buybacks against a share count down about 2% a year are worth tracking, as is auto claim severity, the macro input that determines how much rate increase is enough, over the next 90 days.

Sources: StockTitan (KMPR Q1 2026 8-K), AOL and The Motley Fool (Q1 2026 transcript), StockStory (Q1 deep dive), Quartr, StockAnalysis.

Peer Cohorts (Per Segment, With Filing Citations)

Specialty Property & Casualty Insurance (reported)

Life Insurance (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

View the full interactive KMPR report on boothcheck